EGFR and lung carcinoma: The primary aim of this study was twofold [1]: to develop and validate a ctDNA sequencing assay tailored for Indian cancer patients and [2] to generate real-world data of targetable mutations prevalent in Indian lung cancer patients, providing crucial insights into the prevalence of mutations like EGFR and demonstrating the assay's utility in clinical practice.